Nurix Therapeutics, Inc. filings document the regulatory record of a clinical-stage biopharmaceutical company focused on targeted protein degradation medicines. Its 8-K reports furnish quarterly and annual financial results, corporate presentations, clinical-program updates for bexobrutideg and pipeline programs, and other material events tied to research, development and financing activity.
The company’s SEC disclosures also cover its common stock listed on the Nasdaq Global Market, shelf registration and at-the-market equity distribution arrangements, underwritten equity offerings, and use-of-proceeds language tied to clinical development and research programs. Proxy and governance filings document board composition, director appointments, compensation programs, committee assignments and annual stockholder meeting matters.
Nurix Therapeutics, Inc. reported a Form 4 showing director Roger D. Dansey received a grant of stock options for 31,250 shares of common stock at an exercise price of $15.86 per share. The option vests 100% on the earlier of the next annual stockholder meeting or May 15, 2027, subject to continued service, and expires on May 14, 2036. This is a compensation-related award, not an open-market trade.
Nurix Therapeutics director Roy D. Baynes received a grant of 31,250 stock options to buy Nurix common stock. The options have an exercise price of $15.86 per share and expire on May 14, 2036, providing long-term equity-based compensation.
The award vests 100% on the earlier of the company’s next annual stockholder meeting or May 15, 2027, so long as Baynes continues to provide service through the vesting date. After this grant, he holds 31,250 derivative securities linked to Nurix common stock directly.
Nurix Therapeutics, Inc. director Julia P. Gregory received a grant of stock options covering 31,250 shares of common stock. These options have an exercise price of $15.8600 per share and expire on May 14, 2036.
The award vests 100% on the earlier of the company’s next annual stockholder meeting or May 15, 2027, as long as she continues providing service to the company through that vesting date. This is a compensation-related grant, not an open-market purchase or sale.
Nurix Therapeutics reports Vestal Point Capital and Ryan Wilder collectively hold 6,500,000 shares of Common Stock. The filing states this equals 6.3% of outstanding common stock, based on 103,405,813 shares outstanding as of March 20, 2026. Vestal Point Capital, LP is listed as the investment manager for the fund and account holding the shares; Mr. Wilder is disclosed as CIO and Managing Partner and signs the joint filing agreement.
Nurix Therapeutics, Inc. reported the results of its 2026 annual stockholder meeting held online. A quorum was reached, with 83,747,013 shares of common stock present, representing approximately 80.98% of the voting power entitled to vote as of March 20, 2026.
Stockholders elected three Class III directors—Arthur T. Sands, M.D., Ph.D., Roger Dansey, M.D., and Paul M. Silva—to three-year terms ending at the 2029 annual meeting. Each will serve until a successor is elected and qualified or earlier resignation or removal.
Stockholders also ratified the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending November 30, 2026. In addition, they approved, on a non-binding advisory basis, the compensation of the company’s named executive officers as described in the proxy statement.
Nurix Therapeutics ownership filing: Deep Track Capital, Deep Track Biotechnology Master Fund and David Kroin report beneficial ownership of 6,345,244 shares of Common Stock, representing 6.17% of the class as of 03/31/2026. The filing states this share count is based on 102,843,012 shares outstanding as of 01/23/2026. The statement is a joint filing under Rule 13d-1(k) and identifies Deep Track Capital, LP as the relevant entity for which Mr. Kroin may be considered a control person.
FMR LLC reports 5,541,271.11 shares (5.4%) of Nurix Therapeutics common stock as beneficially owned as of 03/31/2026. The filing of a Schedule 13G states that FMR LLC holds 5,541,271.11 shares with sole dispositive power and sole voting power reported on the cover. The filing also lists Abigail P. Johnson as having shared attribution to the same 5,541,271.11 shares. The filing notes that one or more other persons may have rights to dividends or sale proceeds but no single outside person holds over 5% individually. Exhibit references and a power of attorney are attached.
Nurix Therapeutics, Inc.’s Chief Financial Officer Hans van Houte reported open-market sales of company stock. On May 5, 2026, he sold a total of 14,055 shares of common stock in two transactions pursuant to a previously adopted Rule 10b5-1 trading plan.
The reported sales covered 13,473 shares at $16.5756 per share and 582 shares at $17.1751 per share, each representing a weighted average sale price across multiple trades within stated price ranges.
Nurix Therapeutics, Inc. Chief Legal Officer Christine Ring reported an open-market sale of 8,148 shares of common stock at a weighted average price of $16.9624 per share. The transaction was executed pursuant to a previously adopted Rule 10b5-1 trading plan. Following this sale, she holds 18,305 shares directly.